Veno-ocdusive disease

CALCIUM CHANNEL BLOCKERS BUSULFAN t plasma concentrations of busulfan and t risk of toxicity of busulfan such as veno-ocdusive disease and pulmonary fibrosis, when co-administered with diltiazem, nifedipine or verapamil Due to inhibition of CYP3A4-mediated metabolism of busulfan by these calcium channel blockers. Busulfan clearance may be l by 25%, and the AUC of busulfan may t by 1500 p,mol/L Monitor clinically for veno-ocdusive disease and pulmonary toxicity in transplant patients. Monitor busulfan blood levels as AUC of below 1500 p,mol/L per minute tends to prevent toxicity... 

BUSULFAN CYCLOPHOSPHAMIDE t incidence of veno-ocdusive disease and mucositis when cyclophosphamide is given <24 hours after the last dose of busulfan. Possibly also 1 effect of cyclophosphamide There is l clearance and T elimination half-life of cyclophosphamide, and T concentrations of the active metabolite 4-hydroxycydophosphamide Administer cyclophosphamide at least 24 hours after the last dose of busulfan... 

---